TLDR:
- After the success of Prometheus Biosciences, the team returns with a new biotech called Mirador Therapeutics.
- Mirador Therapeutics raised a massive $400 million in funding to develop precision medicines for inflammatory and fibrotic diseases.
Investors funded the Prometheus team’s new venture, Mirador Therapeutics, with $400 million to address the remaining 75% of patients not treated by their previous therapeutic. Mark McKenna, the CEO, leads the team in developing precision medicines for inflammatory and fibrotic diseases, focusing on gastrointestinal tract, lung, and skin diseases. The funding round was led by Arch Venture Partners, OrbiMed, and Fairmount, among others.
Mirador360 is the platform that drives Mirador Therapeutics, utilizing patient molecular profiles to identify genetic targets for immuno-fibrotic diseases. The company also plans to incorporate a diagnostic component to determine the right patients for specific therapies. The team’s experiences with Prometheus have shaped their approach to building Mirador Therapeutics, emphasizing the importance of solving big problems and executing with speed in the biotech industry. The new venture has already started talks with potential partners at industry events and expects to accelerate into a clinical company soon.
McKenna and his team aim to apply lessons learned from oncology to immunology, focusing on precision medicine and combination approaches to treatment. They plan to advance internal programs into clinical trials and seek external partnerships to enhance their pipeline of therapies. McKenna is confident in Mirador Therapeutics’ ability to move the field of immuno-fibrotic diseases forward with a more refined and accelerated strategy than before.
